These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39076975)

  • 1. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
    Ramonda R; Lorenzin M; Chimenti MS; Atzeni F; Semeraro A; D'Angelo S; Selmi C; Ortolan A; Marchesoni A; Manara M; Luchetti Gentiloni MM; Santo L; Salvarani C; Cauli A; Rossini M; Amato G; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Fracassi E; Giorgio F; Doria A; Foti R; Carletto A;
    Arthritis Res Ther; 2024 Sep; 26(1):172. PubMed ID: 39342310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.
    Ramonda R; Lorenzin M; Sole Chimenti M; D'Angelo S; Marchesoni A; Salvarani C; Lubrano E; Costa L; Dal Bosco Y; Fracassi E; Ortolan A; Ferraioli M; Carriero A; Visalli E; Bixio R; Desiati F; Bergamini A; Pedrollo E; Doria A; Foti R; Carletto A
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090310. PubMed ID: 35510168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
    Christiansen SN; Horskjær Rasmussen S; Ostergaard M; Pons M; Michelsen B; Pavelka K; Codreanu C; Ciurea A; Glintborg B; Santos MJ; Sari I; Rotar Z; Gudbjornsson B; Macfarlane GJ; Relas H; Iannone F; Laas K; Wallman JK; van de Sande M; Provan SA; Castrejon I; Zavada J; Mogosan C; Nissen MJ; Loft AG; Barcelos A; Erez Y; Pirkmajer KP; Grondal G; Jones GT; Hokkanen AM; Chimenti MS; Vorobjov S; Di Giuseppe D; Kvien TK; Otero-Varela L; van der Horst-Bruinsma I; Hetland ML; Ørnbjerg LM
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
    Deodhar A; Machado PM; Mørup M; Taieb V; Willems D; Orme M; Pritchett D; Gensler LS
    Rheumatology (Oxford); 2024 May; 63(5):1195-1205. PubMed ID: 37947318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M; Kiltz U; Kivitz A; Pavelka K; Rohrer S; McCreddin S; Quebe-Fehling E; Porter B; Talloczy Z
    Rheumatol Int; 2022 Feb; 42(2):205-213. PubMed ID: 34773130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
    Mørup MF; Taieb V; Willems D; Rose M; Lyris N; Lamotte M; Gerlier L; Thom H
    J Med Econ; 2024; 27(1):682-696. PubMed ID: 38650583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
    Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
    Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
    Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
    Dougados M; Lardy-Cléaud A; Desfleurs E; Claudepierre P; Goupille P; Ryussen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38428974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.
    Sivera F; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; López-Gómez JM; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martínez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Alegre-Sancho JJ
    Front Med (Lausanne); 2023; 10():1156557. PubMed ID: 37250652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.
    Moreno-Ramos MJ; Sanchez-Piedra C; Martínez-González O; Rodríguez-Lozano C; Pérez-Garcia C; Freire M; Campos C; Cáliz-Caliz R; Calvo J; Blanco-Madrigal JM; Pérez-Gómez A; Moreno-Martínez MJ; Linares L; Sánchez-Alonso F; Sastré C; Castrejón I
    Rheumatol Ther; 2022 Aug; 9(4):1031-1047. PubMed ID: 35467242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.